An Open-label, Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors (NCT05839600)
AE, adverse event, DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; GP, glycoprotein; MTD, maximum tolerated dose; VSV, vesicular stomatitis virus.